A

argenx Tech Stack

Immunology company developing antibody therapies for autoimmune and rare diseases

Biotechnology Research Boston, MA 1,001–5,000 employees Founded 2008 Public Company

argenx is a publicly traded immunology company focused on translating antibody-based medicines into treatments for severe autoimmune diseases. The hiring profile—heavily skewed toward healthcare (47 roles) and research (11 roles), with director-level and senior positions dominating—reflects a late-stage biotech operating model: clinical-stage asset development, market access, and regulatory expansion. Active projects span clinical development execution, provincial market access, and emerging work on multi-agent AI systems for drug discovery, signaling exploration of computational tools alongside traditional R&D.

Tech Stack 18 technologies

Core StackOracle AWS Snowflake Databricks SAS PowerPoint Word Oracle Cloud Azure SQL Visio Excel R CRM LC-MS Veeva CRM Veeva Vault Microsoft Office

What argenx Is Building

◆Challenges

Expanding regulatory team
Identifying unmet medical needs
Expanding pipeline to reach more patients
Expanding market access in quebec
Identifying safety evidence gaps
Ensuring compliance of all studies
Consistency in trial set-up
Patient access challenges
Identifying emerging compliance risks
Control gaps and fraud

▲Active Projects

Clinical development plan (cdp) execution
Provincial market access and stakeholder engagement plans
Advisory boards
Strategic territory plans
Innovation projects for increasing regional team efficiency
Corporate development strategy
Adimanebart (argx-119) development
Reimbursement initiatives
Clinical development of vyvgart
Multi-agent ai systems for drug development

Hiring Activity

Steady110 roles · 40 in 30d

Department

Healthcare

47

Research

11

Legal

7

Ops

5

Sales

5

Finance

4

Data

3

Executive

3

Seniority

Director

35

Senior

34

Lead

18

Mid

9

Manager

7

Junior

3

Intern

2

VP

1

Notable leadership hires: Medical Director, Investor Relations Director, Medical Director Pipeline, Medical Indication Lead, Global Indication Lead

Company intelligence

Find more companies like argenx by tech stack, pain points and active projects

Get started free

About argenx

argenx develops novel antibody-based medicines through partnerships with academic immunology researchers via its Immunology Innovation Program. The company operates across severe autoimmune and rare disease indications, with active clinical development programs and commercialization efforts in multiple geographies. Headquartered in Boston and publicly listed, argenx maintains a global footprint spanning North America, Europe, South America, and emerging markets. The organization structure reflects clinical-stage operations: substantial healthcare and regulatory teams, alongside research, market access, and reimbursement functions.

HeadquartersBoston, MA

Company Size1,001–5,000 employees

Founded2008

Hiring MarketsGermany, Peru, Belgium, United States, France, Italy, Brazil, Canada

Frequently Asked Questions

What is argenx's tech stack?

argenx uses Veeva Vault and Veeva CRM for regulated data and customer management, Snowflake and Databricks for data infrastructure, SAS and R for statistical analysis, Oracle for enterprise systems, and standard Microsoft Office tools. LC-MS is in use for analytical chemistry.

What is argenx working on?

Active projects include clinical development plan execution for pipeline assets, provincial market access and reimbursement initiatives, multi-agent AI systems for drug development, regulatory strategy execution, and corporate development. Notable programs span Vyvgart clinical development, ARGX-119 advancement, and trial consistency improvements.